PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
4.83
Positive P/E while Medical - Pharmaceuticals median is negative at -0.99. Peter Lynch would investigate competitive advantages in a distressed Medical - Pharmaceuticals.
0.32
P/S less than half the Medical - Pharmaceuticals median of 6.79. Walter Schloss would verify if this discount reflects fixable issues. Check margins versus peers.
0.74
P/B less than half the Medical - Pharmaceuticals median of 1.63. Joel Greenblatt would investigate if assets are truly impaired. Check ROE versus peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.74
Fair value ratio less than half the Medical - Pharmaceuticals median of 1.63. Joel Greenblatt would investigate if this discount is justified.
5.17%
Positive earnings while Medical - Pharmaceuticals median shows losses. Peter Lynch would examine earnings quality advantage.
No Data
No Data available this quarter, please select a different quarter.